Amphastar Pharmaceuticals, Inc. (AMPH) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-03-16

Key Insights

Amphastar Pharmaceuticals has authorized a $50 million increase to its share buyback program, indicating confidence in the company's future prospects.
The primary goal of the share buyback program is to offset dilution created by the company's equity compensation programs, which aligns with shareholder interests.
The timing and number of shares repurchased will depend on various factors, including price, corporate and regulatory requirements, and other market conditions.

Want the newest filings?

This analysis covers the filing from 2026-03-16. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-06

Amphastar entered into a supply agreement with Letop Biotechnology, a related party transaction that the Audit Committee approved.
Amphastar amended its contract research agreement with Hanxin Pharmaceutical, another related party transaction approved by the Audit Committee.
The supply agreement and contract research amendment are not considered material to Amphastar's financial condition or results of operations.

Filed: 2026-03-06

Amphastar Pharmaceuticals has entered into new executive employment agreements with two key officers, Jacob Liawatidewi and Rong Zhou, providing them with attractive compensation and severance packages.
The employment agreements include provisions for performance-based annual cash bonuses, equity incentive compensation, and accelerated vesting of equity awards upon a change in control or qualifying termination.
The severance terms provide for substantial lump-sum payments and continued health insurance coverage if the executives are terminated without cause or resign for good reason, particularly in the event of a change in control.

Filed: 2026-01-12

Amphastar Pharmaceuticals has entered into a license agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. to develop and commercialize a corticotropin compound in the United States and Canada. This represents a strategic partnership to expand Amphastar's product portfolio.
The company has also amended its distribution agreement with Hong Kong Genreach Limited, a subsidiary of Hanxin, to expand the regions covered. This could lead to increased revenue opportunities for Amphastar.
Additionally, Amphastar's Chinese subsidiary has amended its manufacturing agreement with Hanxin to expand the territories for certain products, including lidocaine, corticotropin, and semaglutide. This could improve Amphastar's manufacturing capabilities and efficiency.

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.